stockrow
Friday 6 November 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
65.55
0.12
−0.18%
Follow PTCT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
8.64 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.49 | 6.80 | 6.71 | 4.68 | |
P/FCF ratio |
13.62 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(176.27) | (95.22) | 52.44 | (213.65) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.87 | 7.67 | 7.39 | 5.30 | |
EV/EBITDA |
7.53 | 0.00 | 45.79 | 31.91 | |
EV/Operating CF |
9.41 | (29.11) | (244.38) | 583.73 | |
EV/FCF |
15.10 | (13.14) | (24.83) | (23.62) | |
Quick Ratio |
2.20 | 2.29 | 3.20 | 3.05 | |
Current Ratio |
2.35 | 2.44 | 3.39 | 3.27 | |
Net Debt/EBITDA |
(10.33) | 12.55 | 4.27 | 19.10 | |
Debt/Assets |
89.62% | 91.11% | 89.60% | 88.59% | |
Debt/Equity |
(12.65) | (14.49) | (17.61) | (14.86) | |
Asset Turnover |
0.75 | 0.30 | 0.34 | 0.40 | |
Operating CF/Net income |
0.25 | 21.02 | 1.55 | 0.49 | |
Capex/Depreciation |
(0.29) | (0.11) | (0.64) | (0.49) | |
Interest Coverage |
(1.29) | 0.92 | 3.07 | 0.55 | |
Research and Development Expense of Revenue |
80.84% | 37.01% | 27.50% | 29.44% | |
Selling, General and Administrative Expense of Revenue |
58.83% | 31.62% | 22.36% | 22.38% | |
Intangible Assets out of Total Assets |
0.16 | 0.16 | 0.15 | 0.16 | |
Share Based Compensation of Revenue |
11.25% | 8.59% | 6.46% | 6.66% | |
Graham Net Nets |
(0.14) | (0.14) | (0.12) | (0.16) | |
Graham Number |
0.00 | 10.71 | 4.69 | 8.21 | |
Earnings Yield |
11.57% | (3.42%) | (0.60%) | (2.02%) | |
Free Cash Flow Yield |
7.34% | (8.59%) | (4.43%) | (4.79%) | |
Revenue per Share |
2.07 | 3.30 | 4.34 | 4.29 | |
Operating CF per Share |
(0.43) | (0.72) | 1.56 | (0.30) | |
Capex per Share |
(0.03) | (0.02) | (0.09) | (0.07) | |
Free Cash Flow per Share |
(0.46) | (0.73) | 1.47 | (0.38) | |
Cash per Share |
24.46 | 22.93 | 26.85 | 25.49 | |
Shareholders Equity per Share |
(2.58) | (2.19) | (1.99) | (2.29) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.58) | (2.19) | (1.99) | (2.29) | |
Free Cash Flow |
(36.65) | (60.39) | 121.97 | (31.33) | |
Working Capital |
1,305.52 | 1,330.40 | 1,846.29 | 1,761.71 | |
Capital Expenditures |
(2.37) | (1.35) | (7.14) | (6.02) | |
Net Current Asset Value |
(830.13) | (795.57) | (798.48) | (861.14) | |
EV/EBIT |
7.72 | 0.00 | 59.35 | 41.45 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 | |
Price to Operating Income |
6.97 | 0.00 | 53.91 | 36.61 | |
| Other line items | |||||
Average Receivables |
170.09 | 215.21 | 217.59 | 220.57 | |
Average Payables |
342.78 | 315.43 | 360.60 | 371.98 | |
Average Inventory |
51.42 | 48.62 | 62.71 | 81.01 | |
Average Assets |
2,301.90 | 2,762.25 | 2,942.32 | 2,925.71 | |
Average Common Equity |
(651.69) | (183.11) | (185.95) | (173.48) |
Columns are period end dates · fundamentals updated 6 Nov 2026